---
title: "LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293644868.md"
description: "H.C. Wainwright reaffirmed a Buy rating on LB Pharmaceuticals with a $45 price target, citing clinical momentum for LB-102 and regulatory progress in the Phase 3 NOVA-2 schizophrenia trial. Piper Sandler also maintained a Buy rating with a higher $78 target. Analysts highlight the drug's robust trial design, strong cash position, and potential for accelerated approval as key drivers supporting the investment case."
datetime: "2026-07-23T15:25:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293644868.md)
  - [en](https://longbridge.com/en/news/293644868.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293644868.md)
generator: "portal-rs"
---

# LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Ram Selvaraju has given his Buy rating due to a combination of factors tied to LB-102’s clinical and regulatory progress. He views the accelerated timeline for the pivotal Phase 3 NOVA-2 schizophrenia trial and the anticipated pre-NDA meeting with the FDA as materially increasing the visibility and potential speed to approval and commercialization, which supports his unchanged $45 price target.

He also highlights the robust design of NOVA-2 and the ongoing NOVA-3 long-term safety study as foundations for clinically meaningful and regulatory-grade data. In addition, he underscores LB Pharmaceuticals’ strong cash position and extended runway, which should carry the company through several key Phase 2 readouts in bipolar depression and adjunctive major depressive disorder, reinforcing confidence in LB-102’s broader therapeutic potential and the overall investment case. 

In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $78.00 price target.

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [LBRX: LB-102 shows rapid, robust efficacy and safety in late-stage trials, targeting broad neuropsychiatric markets](https://longbridge.com/en/news/295535099.md)
- [LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline](https://longbridge.com/en/news/293470551.md)
- [Denison Mines (DNN) Receives a Buy from Roth MKM](https://longbridge.com/en/news/296056406.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)
- [Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset](https://longbridge.com/en/news/296129081.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**